Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

BACKGROUND: Third-generation tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-TKIs) have proved efficacious in treating non-small cell lung cancer (NSCLC) patients with acquired resistance resulting from the T790M mutation. However, since almost 50% patients with the acquired...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Byoung Soo, Park, Ji Hyun, Kim, Woo Sung, Song, Joon Seon, Choi, Chang-Min, Rho, Jin Kyung, Lee, Jae Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Tuberculosis and Respiratory Diseases 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392490/
https://www.ncbi.nlm.nih.gov/pubmed/28416959
http://dx.doi.org/10.4046/trd.2017.80.2.187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392490/
https://www.ncbi.nlm.nih.gov/pubmed/28416959
http://dx.doi.org/10.4046/trd.2017.80.2.187

Ejemplares similares